NVO

AlphaInsight Score 82/100

Novo Nordisk ADR · Health Care

82
AlphaInsight Score
Momentum64
Valuation52
Growth82
Safety78

Novo Nordisk (US-listed ADR) is the global leader in obesity and diabetes care, with Wegovy and Ozempic scaling worldwide. Competition is arriving, but supply ramp and oral obesity options keep growth elevated.

Market cap
$320B
P/E ratio
24.0
EPS growth
24.0%
Revenue growth
Dividend yield
1.9%
Beta (5Y)
RSI (14)
55

The AlphaInsight Score is a proprietary 0–100 composite of momentum, valuation, growth and safety factors. Research snapshot updated 2026-09-05.

NVO analysis

NVO scores 82 out of 100 on the AlphaInsight composite— higher than roughly 88% of the 656 stocks in our research universe, and #5 among the 73 Health Care names we cover. The composite blends momentum, valuation, growth and safety factors.NVO's strongest pillar right now is growth (82/100), while valuation (52/100) is where the score gives ground.

On the fundamentals: a market capitalization of roughly $320 billion, a P/E ratio of 24.0, trailing EPS growth of 24.0%. The stock pays a dividend yield of about 1.9%.

From a risk and timing standpoint, the 14-day RSI sits at 55, a neutral zone between oversold and overbought; the current technical setup reads: Reclaiming the 50-day MA after a deep, sentiment-driven reset.

NVO operates in the Drug Manufacturers - General industry within the Health Care sector. The bull and bear cases below summarize where our research sees the balance of opportunity and risk in the stock right now.

Bull case

GLP-1 supply scale and oral obesity pipeline extend a decade-long growth runway.

Bear case

Drug-pricing politics could reprice the GLP-1 franchise faster than pipeline can replace it.

NVO FAQ

What is the AlphaInsight Score for NVO?

Novo Nordisk ADR scores 82/100 on the AlphaInsight Score — ranked #75 of 656 stocks in our research universe. It blends momentum (64/100), valuation (52/100), growth (82/100) and safety (78/100).

Is NVO a buy right now?

NVO currently carries an AlphaInsight Score of 82/100 in our research system. Subscribers receive daily entry, target and stop-loss levels whenever it appears in a slate.

What are the biggest risks with NVO?

Drug-pricing politics could reprice the GLP-1 franchise faster than pipeline can replace it.

How does NVO compare to its peers?

Compare NVO head-to-head with LLY, PFE, ABBV on AlphaInsight Scores, valuation, growth and safety factors.

Get the full research on NVO

Subscribers get the complete thesis, risk factors and technical breakdown for NVOand 10 researched ideas every trading day.

Cancel anytime · Secure checkout

Cite & share this research

Ready-to-paste citation snippets for forums, Reddit, X or your own site.

Markdown (Reddit, X, forums)
[NVO stock research — AlphaInsight Score & technical signals](https://alphainsightai.net/stocks/NVO)
HTML (websites, blogs)
<a href="https://alphainsightai.net/stocks/NVO">NVO stock research — AlphaInsight Score & technical signals</a>
Alpha Insight AI provides AI-generated analysis for informational purposes only and is not investment advice. All investing involves risk, including the possible loss of principal.